Page 4 - Alembic Pharmaceuticals

Alembic Pharma shares gain 5% to hit a new high after robust Q1 earnings

The company reported a net profit of Rs 301 crore in Q1FY21, against Rs 124 crore in the year-ago quarter.

Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy

These companies reported an increase in revenue and/or profit before tax for the March quarter

Alembic Pharma sees domestic business growing in double digits this fiscal

Strong brand recall, an efficient sales force, a growing network of supportive doctors and timely product launches are the key catalysts for this business

Alembic Pharma gets USFDA nod for generic Adapalene gel for acne treatment

The product was indicated for the topical treatment of acne vulgaris in patients 12 years of age and older, Alembic Pharma said

Alembic Pharma hits new high, surges 45% in 4 weeks on strong Q4 results

In the past four weeks, Alembic Pharma outperformed the market by surging 41 per cent as compared to Sensex's 1.1 per cent gain

Alembic Pharma hits 52-wk high, rallies 20% in 3 days on robust Q4 numbers

The stock is close to its all-time high level of Rs 792, hit in July 2015

Alembic Pharma surges 10% on strong Q4 results; stock zooms 56% in a month

Last week, the stock hit a fresh 52-week high of Rs 706 on the BSE

Alembic gets USFDA approval for generic doxycycline hyclate tablets

Doxycycline hyclate tablets are indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients

Alembic Pharma's Aleor Dermaceuticals gets USFDA nod for generic product

Alembic now has a cumulative total of 118 ANDA approvals from the USFDA

Alembic Pharma gets final nod from USFDA for infection treatment drug

Azithromycin tablet is a macrolide antibacterial drug indicated for mild to moderate infections

Alembic sees India sales recovering from Q1FY21, expects 10-12% growth

This financial year should see 15-20 product launches in the US

Alembic gets USFDA nod for Tizanidine hydrochloride capsules for spasticity

Drug firm Alembic Pharmaceuticals on Wednesday said it has received final nod from the US health regulator for Tizanidine hydrochloride capsules, used to treat spasticity. "The company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tizanidine Hydrochloride Capsules, 2 mg, 4 mg, and 6 mg," the drug firm said in a regulatory filing. Tizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important. "The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Zanaflex Capsules, 2 mg, 4 mg, and 6 mg, of Covis Pharma BV," the filing said. Tizanidine hydrochloride capsules, 2 mg, 4 mg, and 6 mg have an estimated market size of USD 28 million

Alembic Pharma gets USFDA nod for ointment to treat various skin disease

Alembic said it has a cumulative total of 104 abbreviated new drug application (ANDA) approvals from USFDA

Alembic Pharmaceuticals plans to raise up to Rs 5 bn through issue of NCDs

Alembic Pharmaceuticals board also constituted NCD Committee for issue and allotment of NCDs

Alembic Pharma gets US FDA nod for Xylocaine pain relief ointment

The approved product is therapeutically equivalent to AstraZeneca Pharmaceuticals' Xylocaine ointment, 5 per cent

Alembic Pharma Q2 profit up 64% to Rs 2 bn; revenue at Rs 11.3 bn

International formulations sales grew to Rs 5.87 billion from Rs 2.62 billion in the year-ago period, the company said

Alembic Pharma up 8% as USFDA approves Doxycycline Hyclate capsules

The stock has moved higher by 8% to Rs 530, bouncing back 11% from early morning low of Rs 478 on the BSE.

Alembic Pharma zooms 20% as USFDA gives nod for anti-depression drug

The stock is locked in upper circuit of 20% at Rs 522 after the company received approval from the USFDA for its ANDA Bupropion hydrochloride tablets USP, 75 mg and 100 mg.

Alembic Pharma acquires US-based firm Orit Labs; shares jump nearly 2%

The mid-cap company has equity capital of Rs 37.70 crore. Face value per share is Rs 2

Alembic Pharmaceuticals eyes 50% turnover from US market by 2020

Vadodara-based Alembic Pharmaceuticals, which inaugurated its oncology oral solids facility at Panelav in the Panchmahals district on Friday, 150 km from here, is betting on the segment to drive its US sales in the medium term. It says it expects US sales to contribute to half its revenues by 2020. At present, generic exports account for nearly half its turnover (of Rs 2,986 crore in 2016-17). Pranav Amin, joint managing director, said the contribution of exports (including active pharmaceutical ingredients or bulk drug shipments) to overall turnover would be 60-65 per cent by 2020. "In the next two to three years, the share of international sales in our turnover should be around 60 per cent. The US will have the biggest share, about 50 per cent of our overall turnover, by 2020," he told Business Standard. As a growth strategy, the company has aggressively started investing in the international generics market, with focus on abbreviated new drug applications (ANDAs) and drug master ...